Hyaluronic acid based cancer vaccine - Asahi Kasei Pharma co
Alternative Names: HANG-VaxLatest Information Update: 30 Jan 2026
At a glance
- Originator Asahi Kasei
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer